-
公开(公告)号：US20190263832A1
公开(公告)日：2019-08-29
申请号：US16256773
申请日：2019-01-24
发明人： Masakuni KORI , Toshihiro IMAEDA , Shinji NAKAMURA , Masashi TOYOFUKU , Eiji HONDA , Yasutomi ASANO , Osamu UJIKAWA , Michiyo MOCHIZUKI
IPC分类号： C07D513/04
摘要： Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
-
公开(公告)号：US20240360156A1
公开(公告)日：2024-10-31
申请号：US18592897
申请日：2024-03-01
发明人： Masakuni KORI , Toshihiro IMAEDA , Shinji NAKAMURA , Masashi TOYOFUKU , Eiji HONDA , Yasutomi ASANO , Osamu UJIKAWA , Michiyo MOCHIZUKI
IPC分类号： C07D513/04
CPC分类号： C07D513/04
摘要： Provided is a compound represented by the formula (I):
wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.-
公开(公告)号：US20210179603A1
公开(公告)日：2021-06-17
申请号：US17176861
申请日：2021-02-16
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/14 , C07D417/12 , C07D409/12 , C07D307/79 , C07D407/12 , C07D213/82 , C07D333/38 , C07D413/14 , C07D231/14 , C07D333/40 , C07D285/08 , C07D285/135 , C07D231/12 , C07D277/56 , C07D409/14 , C07D413/12 , C07D307/81
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
公开(公告)号：US20170001994A1
公开(公告)日：2017-01-05
申请号：US15270863
申请日：2016-09-20
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/12 , C07D285/135 , C07D409/12 , C07D413/12 , C07D407/12 , C07D213/82 , C07D417/14 , C07D333/38 , C07D231/14 , C07D307/79
CPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
摘要翻译： 其中每个符号如本说明书中所定义，或其盐。
-
公开(公告)号：US20150291577A1
公开(公告)日：2015-10-15
申请号：US14682695
申请日：2015-04-09
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/14 , C07D409/12 , C07D333/38 , C07D407/12 , C07D213/82 , C07D417/12 , C07D307/79
CPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
摘要翻译： 本发明提供具有赖氨酸特异性脱甲基酶-1抑制作用的化合物，可用作精神分裂症，发育障碍，特别是具有智力障碍的疾病（例如自闭症谱系，Rett综合征， 唐氏综合征，歌舞伎综合征，脆性X综合征，克莱斯特综合征，1型神经纤维瘤病，Noonan综合征，结节性硬化症），神经变性疾病（如阿尔茨海默氏病，帕金森病，脊髓小脑变性（例如，牙周性苍白球萎缩症）和亨廷顿疾病）），癫痫 （例如，Dravet综合征）或药物依赖性等。 由下式表示的化合物，其中每个符号如本说明书中所定义，或其盐。
-
公开(公告)号：US20240317733A1
公开(公告)日：2024-09-26
申请号：US18449326
申请日：2023-08-14
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
CPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubral pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula
wherein each symbol is as defined in the present specification, or a salt thereof.-
公开(公告)号：US20170022222A1
公开(公告)日：2017-01-26
申请号：US15289650
申请日：2016-10-10
发明人： Masakuni KORI , Toshihiro IMAEDA , Shinji NAKAMURA , Masashi TOYOFUKU , Eiji HONDA , Yasutomi ASANO , Osamu UJIKAWA , Michiyo MOCHIZUKI
IPC分类号： C07D513/04
CPC分类号： C07D513/04
摘要： Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
摘要翻译： 其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体增强作用。 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。
-
公开(公告)号：US20160311814A1
公开(公告)日：2016-10-27
申请号：US15203522
申请日：2016-07-06
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/12 , C07D285/135 , C07D409/12 , C07D307/79 , C07D413/14 , C07D213/82 , C07D333/38 , C07D277/56 , C07D417/14 , C07D409/14 , C07D231/12 , C07D407/12
CPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
公开(公告)号：US20150073137A1
公开(公告)日：2015-03-12
申请号：US14540699
申请日：2014-11-13
发明人： Masakuni KORI , Toshihiro IMAEDA , Shinji NAKAMURA , Masashi TOYOFUKU , Eiji HONDA , Yasutomi ASANO , Osamu UJIKAWA , Michiyo MOCHIZUKI
IPC分类号： C07D513/04
CPC分类号： C07D513/04
摘要： Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
-
公开(公告)号：US20190315735A1
公开(公告)日：2019-10-17
申请号：US16455359
申请日：2019-06-27
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/14 , C07D333/38 , C07D413/14 , C07D407/12 , C07D307/79 , C07D409/12 , C07D417/12 , C07D307/81 , C07D413/12 , C07D409/14 , C07D231/12 , C07D277/56 , C07D285/135 , C07D285/08 , C07D333/40 , C07D231/14 , C07D213/82
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.043 秒)
